Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is a glycoprotein that is part of the carcinoembryonic antigen and the immunoglobulin superfamilies. We have shown that it functions as a tumor suppressor and that this function depends upon the presence of the longer CEACAM1 cytoplasmic domain. In this report, we describe the generation of a Ceacam1À/À mouse. The Ceacam1À/À colon exhibits increased in vivo proliferation relative to the wild-type counterpart with a corresponding decreased expression of the p21
Introduction
Carcinoembryonic antigen (CEA) is recognized as an important tumor marker used clinically to follow the progression of colorectal cancer (Gold and Freedman, 1965) . Carcinoembryonic antigen is part of the large immunoglobulin-like CEA gene family comprising as many as 31 genes , all located on chromosome 19q13.2 in humans (Olsen et al., 1994) . Twenty of these genes are expressed in a variety of normal and tumor epithelial, hematopoietic cells and in placenta . Orthologs have been found in the mouse and rat genomes . Contrary to CEA that is widely overexpressed in human colorectal tumors (Cournoyer et al., 1988) , the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) gene is markedly downregulated in human (Neumaier et al., 1993) and mouse (Rosenberg et al., 1993) colon cancer. Carcinoembryonic antigenrelated cell adhesion molecule 1 expression is also considerably diminished in human prostate (Hsieh et al., 1995; Busch et al., 2002) , breast (Luo et al., 1997; Huang et al., 1998) , liver (Hixson et al., 1985; Tanaka et al., 1997) , endometrial (Bamberger et al., 1998) and bladder cancers (Kleinerman et al., 1996) . Carcinoembryonic antigen-related cell adhesion molecule 1 decreases early in the development of cancer, being absent from hyperplastic colonic aberrant crypt foci and hyperplastic polyps (Nittka et al., 2004) , microadenomas (Ilantzis et al., 1997) and adenomas (Nollau et al., 1997a) , and in hyperplastic prostate . These results have also been confirmed using gene chip techniques on patient samples (Zhang et al., 1997; Buckhaults et al., 2001; Notterman et al., 2001) . One mechanism regulating the tumor suppressive activity of CEACAM1 in prostate cancer is attributed to the enhanced expression of the Sp2 transcriptional repressor, a member of the Sp family of transcription factors. This factor binds to the CEACAM1 promoter in vitro and in vivo where it recruits histone deacetylase; consequently, the CEACAM1 promoter is hypoacetylated in prostate cancer cells and the CEACAM1 protein is significantly decreased (Phan et al., 2004) . However, CEACAM1 is not always downregulated in cancer. Overexpression of CEACAM1 is indicative of disease progression and metastasis in melanomas (Thies et al., 2002) , lung adenocarcinomas (Muenzner et al., 2000; Laack et al., 2002) and gastric carcinomas (Kinugasa et al., 1998) .
The CEACAM1 tumor suppressor function has been studied by modulating the expression of this glycoprotein in colonic and prostatic cancer cell lines. Expression of the CEACAM1-L protein (with a long 73 amino-acid cytoplasmic domain) in the mouse CT51 colonic carcinoma cell line revealed that expression of the longer CEACAM1 isoform reduced the number of colonies in a clonogenic assay, whereas the CEACAM1-S-expressing cells (with a short 10 amino-acid cytoplasmic domain) behaved as the wild-type cells. This result suggested that CEACAM1-L played a role in inhibition of tumor cell growth (Kunath et al., 1995) . The ability of CEACAM1-L to function as a tumor suppressor was confirmed in vivo as CEACAM1-L-transfected CT51 cells significantly diminished the number and size of tumors formed in syngeneic BALB/c mice (Kunath et al., 1995) . Similarly, human PC-3 prostatic cells transfected with CEACAM1-L abolished tumor development in nude mice (Hsieh et al., 1995) .
The CEACAM1-L tumor suppressor function is independent of its function as an intercellular adhesion molecule since deletion of the first Ig domain of the rat (Luo et al., 1997) and mouse CEACAM1, responsible for its cell adhesion activity (Cheung et al., 1993) , did not affect tumor development in vivo. The long cytoplasmic domain contains several binding motifs including 17 Ser/Thr residues and two Tyr residues phosphorylated by a variety of kinases in different cells. Indeed, the presence of a phosphorylated Tyr488, located within an Immunoreceptor Tyrosinebased Inhibitory Motif (ITIM) (Ravetch and Lasnier, 2000) , is critical for inhibition of tumor development in vivo (Luo et al., 1997; Izzi et al., 1999) , as is the presence of Ser503 (Estrera et al., 2001; Fourne`s et al., 2001) and that of the last three Lys residues . When both CEACAM1-S and CEACAM1-L are introduced tandemly into the CT51 colonic carcinoma cells, the tumor inhibitory function then depends on the ratio of these two isoforms (Turbide et al., 1997) .
In this manuscript, we provide complete information on the generation of the Ceacam1À/À mouse. Deletion of CEACAM1 produced an increased rate of proliferation in the colonic crypt with a decreased rate of apoptosis. Correspondingly, the p21 Cip1 and p27
Kip1
CDK inhibitors were decreased in Ceacam1À/À colonic cells. Clinical pathology of tissues in older Ceacam1À/À mice did not reveal any tumor, suggesting that CEACAM1 is likely not involved in initiation of tumorigenesis. Azoxymethane carcinogen treatment induced not only a greater number of tumors, but also larger tumors, in the colon of CEACAM1-deficient mice relative to their wild-type counterparts. The size of the tumors in the Ceacam1À/À mice was also increased relative to those found in the WT controls. These results, therefore, suggest that CEACAM1 inhibits the progression of colon tumors in vivo.
Results

Generation of the Ceacam1À/À mice
The strategy leading to complete abrogation of CEACAM1 expression in mice was based on the removal of the first two exons of the Ceacam1 gene (Figure 1a-c) . The initiator ATG codon is positioned in the first exon and most functions associated with the CEACAM1 protein depend on the presence of the first Ig-like domain encompassed within the second exon. For this purpose, an Xba1-Xho1 restriction fragment encoding these two exons was removed from the gene and a cassette encoding the thymidine kinase (TK) promoter and the neo r gene was inserted (Figure 1b) . The targeting vector was electroporated into mouse R1 ES stem cells and 33 positive clones out of 830 were isolated after selection in G418-containing medium. A Southern blot was hybridized with a 32 P-labelled probe specific to the neo r gene (Figure 1c , probe 3) to confirm the targeting event and the number of integration sites in the þ /À ES cell clones. The two selected ES cell clones (2D2 and 11H11) both produced a single 9.4 kb fragment positive for the neo probe (Figure 1g ). Four chimeric male mice were obtained by microinjection of the ES cell lines (2D2 and 11H11) into C57Bl/6 mouse blastocysts and transmitted the Ceacam1-targeted allele through the germline. The heterozygous Ceacam1 þ /À progeny mice were mated to produce homozygous mice. Mice ( þ /À and À/À) derived from these two ES cell lines were positive for the neo probe, although the 11H11-derived mice appeared to have two neo-positive fragments relative to a single fragment observed in the originating ES cell line and the 2D2-derived mice (Figure 1g ). The targeting event was also confirmed by hybridizing the genomic blots with a Ceacam1-specific probe ( Figure 1a , probe 2). In this case, the 12.3 kb EcoR1 restriction fragment was positive for this probe in the þ / þ and þ /À mice, but was negative in the À/À mice. Interestingly, the Ceacam1-targeted mice exhibited a 7.0 kb 129/Sv Ceacam2 fragment after breeding instead of the approximate 9.0 kb fragment in C57Bl/6 mice ( Figure 1f ). Since the EcoR1 sites of the Ceacam2 fragments detected by the probe used are located within the promoter region and intron 2, the size of the gene product is not modified. The targeting event was also confirmed with other characteristic restriction digests of the 2D2 and 11H11 ES cell genomic DNA (data not shown). The frequency of germline transmission was calculated to be 22% on a mixed background (C57Bl/6, BALB/c, 129Sv). Mating of heterozygous mice produced expected Mendelian ratios of Ceacam1À/À offspring (1.0 þ / þ : 1.8 þ /À: 0.9 À/À). CEACAM1 is expressed in ovary and prostate, yet its abrogation had no incidence on gender ratios (53% males: 48% females).
Abrogation of CEACAM1 expression in Ceacam1-targeted mice The complete abrogation of CEACAM1 expression was verified by reverse transcription-polymerase chain reaction (RT-PCR) and Western blotting. Total RNA prepared from colon and kidney of several mice from each litter was subjected to RT-PCR. The þ / þ and þ /À mice were positive for the Ceacam1 mRNA whereas no Ceacam1 mRNA was present in the CEACAM1 in colon cancer progression N Leung et al Ceacam1À/À colon of mice ( Figure 2a) . No changes were detected in the amount of Ceacam2 cDNA amplified from kidney mRNA, suggesting that this second Ceacam-like gene remained intact in the Ceacam1 knockout mice. Gapdh mRNA was used as an internal control. These results indicated that the gene inactivation strategy completely abrogated the transcription of Ceacam1 (Figure 2a ). The expression of the CEACAM proteins in mouse colon and kidney tissues were examined by immunoblotting total proteins from several different mice with polyclonal anti-CEACAM1 and anti-CEACAM2 antibodies (Figure 2b ). In both these tissues and others (data not shown), expression of all CEACAM1 isoforms in the homozygous mice was completely eliminated relative to expression in the wildtype or heterozygous mice (Figure 2b ). Actin levels, as controls for loading, were constant in these tissues Figure 1 Gene targeting of the mouse carcinoembryonic antigenrelated cell adhesion molecule 1 (Ceacam1) gene. The Ceacam1 gene contains nine exons represented by the white boxes. The ATG initiator codon is located in the first exon of the gene. Two alternate stop codons are present in exons 8 and 9 of the gene; their respective usage gives rise to two different Ceacam1 mRNAs. The protein domains encoded by the various exons are indicated underneath the gene structure (a). A targeting vector was engineered by replacing a Xba1-Xho1 fragment encompassing the first two exons, the first intron and part of the second intron of the Ceacam1 gene by a Tk-neo r cassette (b). Cleavage of the wild-type 129/Sv Ceacam1 gene with EcoR1 produces a 12.3kb restriction fragment. Insertion of the Tk-neo r cassette introduces a novel EcoR1 site in the recombinant targeted allele, thereby producing a 1.7 kb EcoR1 restriction fragment, as detected using a BamH1-Hind111 93 bp probe (probe 1) located in the Ceacam1 promoter outside of the targeting vector (c and d). This same probe binds to the promoters of the 129/Sv and C57Bl/6 Ceacam2 and Ceacam10 genes (d). Ceacam1-(e) or Ceacam2-specific probes (f) (probe 2) located in the first Ig domains (Ne´dellec et al., 1995) were used to hybridize to the same Southern bolt. A neo-specific probe (Blau et al., 2001 ) (probe 3) was hybridized to the same blot (g). (Ceacam1) and Ceacam2 transcripts and proteins. Total RNA was prepared from colon and kidney of mice from each mouse lines (2D2 and 11H11) and used to generate cDNAs via RT-PCR using Ceacam1, Ceacam2 or Gapdh primers as described in Materials and methods. After 40 (Ceacam1 and Ceacam2) or 30 (Gapdh) rounds of amplification, respectively, samples were loaded on a 1.0% agarose gel and subjected to electrophoresis. The gels were photographed after staining the gels with ethidium bromide (a). Protein lysates were prepared from mouse colon (b, top panel) or kidney (b, middle panel) and equal amounts of protein were separated on 8.0% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels. The proteins were transferred to Immobilon membranes and immunoblotted with polyclonal anti-Ceacam1 (b, top panel) or antiCeacam2 (b, middle panel) antibodies. Specificity of the antibodies was confirmed using purified CEACAM1 (CC1) or CEACAM2 (CC2) protein samples. Equal loading of proteins was confirmed by immunoblotting with an anti-actin antibody (b, bottom panel).
CEACAM1 in colon cancer progression N Leung et al ( Figure 2b ). In kidney extracts, the amount of the CEACAM2 protein revealed with a specific anti-CEACAM2 polyclonal antibody (Robitaille et al., 1999) remained constant in all genotypes, in line with the actin control.
CEACAM1-deficient mice show increased proliferation and decreased apoptosis in their colon Wild-type mice express the two major CEACAM1 isoforms in their colon albeit in different amounts. We have previously shown that the CEACAM1-L isoform is only expressed at approximately one-seventh the level of CEACAM1-S in colon tissue and that it reduces the proliferation of mouse CT51 colonic carcinoma cells. The CEACAM1-S isoform, although predominantly expressed in normal colon, does not influence cell proliferation but it has been shown to participate in apoptosis in a breast 3D lumen formation assay and in HT29 colon carcinoma cells. As both isoforms are tandemly expressed in this tissue and were both eliminated by the genetic ablation procedure, we examined whether elimination of the CEACAM1 isoforms affected proliferation or apoptosis of colonic epithelial cells. Staining of colon sections from wild-type mice with a polyclonal antibody specific to CEACAM1 (Ab 2457) demonstrated that, contrary to what has been observed in human colon (Frangsmyr et al., 1999) , CEACAM1-positive cells were found in the bottom of the colonic crypt which is the proliferative zone (Figure 3a) . Similar results were obtained with the CC1 monoclonal antibody. Colon sections of 3-monthold þ / þ and Ceacam1À/À littermates (five and six mice, respectively) were stained with an antibody to proliferating cell nuclear antigen (PCNA). A proliferation index was calculated by counting PCNA-positive cells of five different microscope fields over the total number of cells in the villi. Ceacam1À/À colon revealed a 30% increase in the number of proliferative cells as compared to those of the wild-type mice (Po0.05, Figure 3b ). Staining of colon sections for BrdU after a 2 or 6 h in vivo labeling period produced similar results (data not shown). Similarly, examination of BrdUpositive colonic cells migrating from the bottom of the crypt to the top after a 24 h BrdU incorporation indicated that the rate of migration was identical in the wild-type and CEACAM1-null mice.
In the colon, proliferation occurs in stem cells located at the bottom of the colonic crypts (Potten and Loeffler, 1990) . As differentiation proceeds, these cells move upwards finally undergoing apoptosis at the top of the crypt and are then extruded into the gut lumen. We studied whether elimination of the CEACAM1 isoforms affected the rate of early apoptosis in this tissue by measuring Annexin V labeling of dissociated colonic cells. Labeling was decreased by approximately 50% in knockout colonic cells compared to those of the wildtype mice in two separate experiments comprising five animals of each genotype (Po0.001, Figure 3c and d). Tissue sections were also processed using terminal deoxynucleotidyl transferase-mediated dUTP nick endlabeling (TUNEL) assays as a measure of late-stage apoptosis. Calculations of the labeling index, in five different microscope fields for all mice, indicated that apoptosis was weaker in the CEACAM1 knockout animals (WT, 0.12070.01 versus KO, 0.10970.01, P ¼ 0.065) (data not shown). These combined results suggest that disruption of the Ceacam1 gene, leading to the elimination of all isoforms, produces an overall increased rate of colonic proliferation in tandem with a decreased rate of apoptosis in vivo. However, early apoptosis was decreased to a greater extent, possibly due to tissue processing to obtain single cell suspensions for flow cytometry.
We then evaluated whether the increased rate of proliferation in the CEACAM1-null colon influenced the expression of Cdk inhibitors p21
Cip1 and p27 Kip1 . Nuclear fractions were prepared from eight pairs of wild-type and Ceacam1À/À colonic cells and proteins were immunoblotted using antibodies specific for these two proteins (Figure 3e ). Quantification of both the p21
Cip1 and p27 Kip1 proteins demonstrated that expression in the CEACAM1-deficient mice was reduced by 56% for p21 Cip1 (Po0.05) and 66% for p27 Kip1 (Po0.005) relative to the þ / þ controls (Figure 3f ). This suggests that elimination of CEACAM1 modulates cell cycle regulation in these mice.
CEACAM1-deficient mice do not develop tumors spontaneously
Carcinoembryonic antigen-related cell adhesion molecule 1 is downregulated and generally absent in human colorectal tumors. We questioned whether Ceacam1À/À mice might, therefore, develop colon tumors as they aged. We examined 35 litters comprising 111 mice of Ceacam1À/À and þ / þ mice of the second and third backcrosses in C57Bl/6 and 129Sv backgrounds at regular intervals of 6, 12, 18 and 22 months and all tissues normally expressing CEACAM1 were retrieved and processed for histological analyses. No tumors were detected macroscopically in any of these tissues. Microscopically, no changes were seen in the structure of the colon, intestine, prostate, breast, ovary, uterus, kidney, thymus or brain of the Ceacam1À/À mice relative to the same structures observed in the wild-type mice. Thus, although the number of mice examined is still too low to detect a rare tumor event, it appears that CEACAM1 does not play a role in initiation of tumor development.
Azoxymethane-treated CEACAM1-deficient mice exhibit enhanced tumorigenesis Carcinogen induction is a widely used procedure for studying changes in the molecular and pathological process of tumor development. The methylating agent azoxymethane (AOM) specifically targets the colon . Genetic modifications found in human colon cancer (Fearon and Vogelstein, 1990) have been identified in carcinogen-treated animals including mutations in K-ras (Vivona et al., 1993) , p53 (Okamotu et al., 1995; Singh et al., 1997) , Adenomatous polyposis coli (APC) (Maltzman et al., 1997) , cyclin D1 (Wang et al., 2000) and the b-catenin protein (Takahashi et al., 2000) . To gauge whether CEACAM1 contributes to colon tumor progression in vivo, mice were injected repeatedly with AOM. Less than 5% of the mice had to be killed before the experimental end point. After 19-20 weeks, mice were euthanized, their colons removed and all other organs were thoroughly examined, in particular, the liver and lung, which are common sites of metastases in human colon cancer. No aberrant growths were found in any tissue other than the colon. In backcross three mice, Ceacam1À/À mice demonstrated an overall threefold increase in the number of colon tumors relative to those found in C57Bl/6 control mice (6.0070.09 versus 2.3870.07, Po0.01) ( Figure 4A, panel a) . The average size of these tumors was also greater in Ceacam1À/À mice than in wild-type mice ( Figure 4A, panel b) Figure 4A , panel c) indicating a more rapid progression in the development of these tumors than those found in the wild-type control mice.
In backcross eight Ceacam1À/À mice and their wildtype siblings, the Ceacam1À/À mice again developed a significant increase in the number of tumors relative to those found in the WT mice (WT, 2.370.36 versus KO, 3.970.81, Po0.05) ( Figure 4B ). The Ceacam1À/À mice also had larger tumor sizes (WT, 2.67 mm 2 70.57 versus KO, 3.79 mm 2 72.56, P ¼ 0.13). The large tumors were examined and classified according to clinical standards. Adenomas were defined as proliferations of the colonic epithelium with at least low-grade dysplasia. A diagnosis of high-grade dysplasia required increased cytological atypia and architectural complexity. The term intramucosal carcinoma was used when there was evidence of invasion into the lamina propria, characterized by prominent back-toback glands and a cribriform architecture, but without invasion into the submucosa. In humans, intramucosal carcinoma is categorized as 'in situ' carcinoma, as it is considered to have no potential for metastasis. A diagnosis of invasive adenocarcinoma was made when invasion into the submucosa was identified. Most samples contained adenomas with at least high-grade dysplasia (Figure 5a ). Tumors from the CEACAM1-deficient mice were generally classified as intramucosal carcinomas (Figure 5b ) with a minimal (o2%) number of tumors having invaded the submucosa (Figure 5c, d) . Tumors from both the þ / þ and Ceacam1À/À mice were analysed for expression of E-cadherin and bcatenin. There were essentially no differences in localization of E-cadherin between colon tumors of þ / þ and À/À mice. Tumor cells (15-20%) exhibited nuclear expression of b-catenin, as is often seen in colon tumors (Brabletz et al., 2002; Wong et al., 2004) . In summary, these results confirm that deletion of CEA-CAM1 contributes to the progression of colon cancer. Carcinoembryonic antigen-related cell adhesion molecule 1-L is normally expressed in the endothelium. We questioned whether abrogation of its expression modified angiogenesis in the colonic tumors. To investigate this, we quantified CD31 staining, a measure of vascular density, on tumor sections from wild-type, heterozygous and homozygous Ceacam1-deficient mice. No significant differences in vascular density were measured between these tumors. This suggests that the loss of CEACAM1 in endothelium does not alter colon tumor angiogenesis and that the progression of tumors is due to elimination of CEACAM1 in epithelial cells.
Discussion
Carcinoembryonic antigen is widely used clinically as a measure of colorectal tumor recurrence. Recent studies have also suggested that CEACAM1 and CEACAM6 also play a significant role in colonic tumor development (Neumaier et al., 1993; Nollau et al., 1997a, b; Scholzel et al., 2000; Jantscheff et al., 2003) . As the mouse neither expresses CEA nor CEACAM6 and relies for most of its CEA-related functions on the expression of CEACAM1, studies investigating the role of these proteins depend on the generation of adequate transgenic mouse models (Chan and Stanners, 2004) or the availability of mice deficient for CEACAM1. In this manuscript, we describe the generation of the Ceacam1À/À mouse. In order to gain some understanding into the function of CEACAM1 in colonic homeostasis, we have examined the proliferation and apoptotic responses in Ceacam1À/À mouse colon as well as gauged the sensitivity of these animals to colon cancer development.
Elimination of the CEACAM1 isoforms has changed the growth properties of colonic crypts. Crypts are lined with epithelial cells formed by the proliferation of stem cells located at the bottom. As these epithelial cells mature, they migrate up the length of the crypt and differentiate until they reach the apex that constitutes the area of extrusion into the lumen and anoikis (Potten and Loeffler, 1990) . We have shown that in mouse colon, CEACAM1 is indeed expressed at the bottom of the crypt and therefore its elimination accelerates proliferation, confirming the function of CEACAM1-L defined in a number of epithelial cell lines as a regulator of cell proliferation (Hsieh et al., 1995; Kunath et al., 1995; Singer et al., 2000) . In addition, CEACAM1 is also abundantly expressed in the upper third of the colonic crypt that undergoes differentiation. The p21
Cip1
and p27
Kip1 proteins are responsible for the induction of differentiation in intestinal epithelium (Quaroni and Beaulieu, 1997; Deschenes et al., 2001) . The significant decrease in expression of CDK inhibitors p21
Cip1 and p27
Kip1 observed in Ceacam1À/À colon suggests that the induction of differentiation programs may be slowed with colonic cells consequently undergoing a higher proliferation rate. In support of this, one of the genes demonstrating increased expression in dnTCF-induced LS174T cells was CEACAM1. Downregulation of TCF activity by expression of the dnTCF construct in colonic cell lines resulted in induction of p21
Cip1
, G1 arrest and differentiation (van de Wetering et al., 2002) . The Ceacam1À/À mice also show a reduced rate of apoptosis. This was more apparent in the early phases of apoptosis as measured by Annexin V labeling.
Downregulation of CEACAM1 in tumorigenesis is a very early phenomenom as CEACAM1 is considerably decreased or absent in colorectal hyperplastic polyps (Nittka et al., 2004) or adenomas (Nollau et al., 1997a) and in hyperplastic prostate . Although the number of mice examined was too small to detect a rare genetic event, no tumors developed without carcinogen induction, demonstrating that CEACAM1 is apparently not involved in the initiation of tumors. However, its downregulation in benign lesions suggests that it is likely a gene modified early in the progression of the disease once the tissue has accumulated defined genetic mutations. In this context, we have treated mice with azoxymethane, a carcinogen that specifically induces the development of colon cancer by mutating a significant number of genes (Vivona et al., 1993) . Adenomatous polyposis coli (APC) is thought to be the first gene altered in the colon cancer genetic cascade resulting in truncation of the protein and consequently, modification of the b-catenin transcriptional activity (Kinzler and Vogelstein, 1996; Fodde et al., 2001) . Experiments are currently under way to determine whether introducing an Apc truncating mutation (Fodde et al., 1994) on the Ceacam1À/À background will lead to enhanced intestinal tumor development.
A number of studies have shown that CEACAM1-L is expressed in newly-forming immature blood vessels of tumors and those resulting from physiological angiogenesis as seen in wound healing and endometrial proliferation (Ergu¨n et al., 2000; Volpert et al., 2002; Oliveira-Ferrer et al., 2004; Muller et al., 2005) . As the targeting of Ceacam1 also eliminated the expression of CEACAM1 in endothelial cells, we examined whether the angiogenic properties of the carcinogen-induced tumors was in any way affected by the lack of CEACAM1 expression. The vascular density from all three genotypes did not show statistically significant differences in these conditions (data not shown). However, vascular density may not be a faithful readout of the angiogenic status in colon cancer, as discussed by Eberhard et al. (2000) . We have investigated the angiogenic status of Ceacam1À/À mice, and blood vessels show enhanced vascular structural defects leading to leakage in neo-angiogenic conditions and therefore failed to establish new capillaries in Matrigel plug assays. Furthermore, Ceacam1À/À mice showed reduced growth of arterioles and collateral blood flow was reduced after induction of hindlimb ischemia by femoral artery ligation (Horst et al., 2006) . Thus, endothelial growth may also be affected in Ceacam1À/À tumoral angiogenesis.
The results presented in this manuscript highlight the importance of CEACAM1 in regulating proliferation in the colon and to that effect, its elimination renders the colon more sensitive to carcinogen-induced tumor CEACAM1 in colon cancer progression N Leung et al development. The contribution of epigenetic and genetic changes to the development of CEACAM1-deficient tumors is currently being addressed.
Materials and methods
Generation of the Ceacam1 knockout mice
The strategy leading to complete abrogation of CEACAM1 expression in mice was based on the removal of the first two exons of the Ceacam1 gene (Figure 1a-c) . The strategy used was to eliminate the initiator ATG codon and the second exon since many CEACAM1 functions depend on the presence of the first Ig-like domain encompassed by the second exon. A Xba1-Xho1 restriction fragment encoding the two exons was removed from the gene and replaced by a cassette encoding the TK promoter and the neo r gene (Figure 1b) . The targeting vector was electroporated into mouse R1 ES stem cells and ES cell clones were isolated after selection for 8 days in the G418-containing medium. The targeting event was evaluated by Southern analyses of EcoR1-digested genomic ES cell DNA using a 32 P-labelled BamH1-HindIII probe ( Figure 1c , probe 1). The Southern blot was then hybridized with a 32 P-labelled probe specific to the neo r gene (Figure 1c , probe 3) to confirm the targeting event and the number of integration sites in the þ /À ES cell clones. Chimeric mice were generated by microinjection of the ES cell lines (2D2 and 11H11) into C57Bl/6 mouse blastocysts. The heterozygous Ceacam1 þ /À progeny mice were mated to produce homozygous mice. The targeting event was also confirmed by hybridizing the genomic blots with a Ceacam1-specific probe ( Figure 1a , probe 2) and confirmed with other characteristic restriction digests of the 2D2 and 11H11 ES cell genomic DNA (data not shown). Experiments were performed in the C57Bl/6 background on backcrosses # 2, 3 and 8 for both the 2D2 and 11H11 Ceacam1À/À mice. Mice were handled according to the standards defined by the Canadian Council on Animal Care.
Genotyping
Genotyping was performed using o1 cm of tails clipped from 3-week-old pups. Genomic DNA was prepared using a 'DNeasy Tissue' kit (Qiagen, Mississauga, ON, Canada) . Approximately 5 mg of genomic DNA was cleaved with EcoR1 and separated on 0.75% agarose gels. The DNA was transferred to Hybond XL membranes (Amersham Biosciences, England) and hybridized at 421C for 18 h with 2-4 Â 10 6 d.p.m. of random-primed 93 bp a-32 P-dATP-labeled BamH1-HindIII fragment cleaved from within the Ceacam1 promoter in a region located outside of the targeting vector was used as a probe (Ne´dellec et al., 1995) . Membranes were washed at a final stringency of 651C in a 0.1 Â SSC and 0.1% sodium dodecyl sulfate (SDS) solution. Alternatively, the mice were genotyped by PCR amplification of their genomic DNA in a final volume of 15 ml containing a 3 Â dilution of the Vent polymerase buffer supplied by the manufacturer, 500 mM of dNTPs, 5 ng/ml of the Ceacam1-specific oligonucleotides (PN8, 5 0 CTGCCCCTGGCGCTTGGA and PN5, 5 0 TACATGAAA TCGCACAGTCGC) and 5 ng/ml of the neo r -specific oligos (neoforward, 5 0 CGGTGCCCTGAATGAACTGC and neoreverse, 5 0 GCCGCCAAGCTCTTCAGCAA) and 0.4 U of Vent polymerase (New England Biolabs, Beverly, MA, USA). Amplifications proceeded through 30 cycles of 20 s at 941C, 30 s at 571C and 30 s at 721C. The wild-type þ / þ mice produced a Ceacam1 fragment of 250 bp upon agarose gel electrophoresis, whereas the homozygous À/À mice had a 550 bp neo fragment and the heterozygous þ /À mice showed both fragments.
Reverse transcription-polymerase chain reaction RNA was isolated from colon or kidney tissue following Invitrogen's TRIzol Reagent protocol. Synthesis for amplification of the Ceacam1, Ceacam2 and Gapdh cDNAs was performed at 421C for 1 h using 200 U of Superscript II reverse transcriptase (Invitrogen, Burlington, ON, Canada) according to manufacturer's protocol. Total RNA (5 mg) were primed with primer 5 0 TTGATACCTCACTCTCAGCCA for Ceacam1 cDNA; 20 mg of RNA with primer 5 0 GGCTCCAG GATCCACCTTTTCTTC for the Ceacam2 cDNA; and 4 mg of RNA with primer 5 0 GACTCGAGTCGACGGTACCCT 17 were used for the Gapdh cDNA. One tenth of the cDNAs were then used for PCR amplification with Vent polymerase (New England Biolabs) with 50 ng/ml of the following primers: Ceacam1 forward, 5 0 CCAAATGATCACCATGAAG, Ceacam1 reverse, 5 0 GGCTCCAGGATCCACCTTTTCTTC; Ceacam2 forward, 5 0 ATGGCTTTTCCACTCCACGC, Ceacam2 reverse, 5 0 GTCTTATTAGTGCCTGTTAC; Gapdh forward, 5 0 CCATGGAGAAGGCTGGGG, Gapdh reverse, 5 0 CAAA GTTGTCATGGATGACC.
Nuclear extract preparations
Epithelial cells were collected from the colonic mucosa by scraping with a scalpel blade and rinsed with phosphatebuffered saline (PBS) containing protease inhibitors. Cells were resuspended in two packed-cell volumes of buffer A (10 mM HEPES, pH 7.9 containing 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM DTT and NP-40 0.05%). After 20 min of incubation on ice, cells were mechanically disrupted by five passages through 21 G needles and centrifuged at 5000 g for 5 min at 41C. Cells were washed once with buffer A and resuspended in buffer C (20 mM HEPES pH 7.9 containing 25% glycerol, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM DTT and 1 mM PMSF) by rotating for 30 min at 41C. Nuclear pellets were collected by centrifugation at 13 000 r.p.m. for 30 min at 41C and protein concentration was evaluated using a Bio-Rad protein assay kit.
Western analyses
Protein samples were prepared from cell (Huber et al., 1999) or nuclear lysates. Proteins were transferred to Immobilon P membranes (Millipore, Bedford, MA, USA). The membranes were blocked with 5% non-fat milk in 0.1% Tween-TBS for 30 min and incubated with primary and secondary antibodies for 2 h. CEACAM1 and CEACAM2 were detected using rabbit polyclonal Abs 2457 and 2052, respectively. Antibodies to p27
Kip1 and to p21 Cip1 were from BD Biosciences, Mississauga, ON, Canada, and antibodies to actin were from Sigma. ECL Western Blotting Reagents and secondary antibodies (a-mouse-HRP and a-rabbit-HRP antibodies, Amersham Biosciences, England) were used for detection.
Preparation of tissues, histological analyses and antibodies used The mice were killed by cervical dislocation and tissues were removed, washed in PBS and fixed in 4% paraformaldehyde/ PBS or 10% phosphate-buffered formalin and processed for immunohistochemistry. Fixed tissues were dehydrated in ethanol and paraffin-embedded. Tissue sections, 4 mm in thickness, were deparaffinized according to standard protocol. Slides were microwaved in citric acid buffer to improve antigen availability. Sections were blocked in 1% BSA and 5% normal serum. Primary antibody was applied for 18 h at 41C. Appropriate secondary and tertiary antibodies (DakoCytoma-tion, Mississauga, ON, Canada) were applied and DAB was used for colour development. Slides were counterstained with hematoxylin, following standard histological procedures. The following antibodies were used according to manufacturer's instructions: anti-BrdU (Sigma, St Louis, MO, USA), PCNA (Santa Cruz), TUNEL (Roche, Diagnostic, Laval, QC, Canada), E-cadherin (BD Biosciences, Mississauga, ON, Canada), b-catenin (BD Biosciences). The anti-CEACAM1 (2457) (Hemmila et al., 2004) and anti-CEACAM2 (2052) (Robitaille et al., 1999) antibodies are polyclonal rabbit antibodies raised to purified proteins.
To define vascular density in tumors, paraffin sections were deparaffinized and treated for 10 min with trypsin (0.01 g trypsin, 0.01 g CaCl 2 /ml H 2 O). Sections were blocked in 1% BSA and 5% normal goat serum. Primary antibodies, anti-CD31 from Pharmingen and anti CEACAM1 pAb 2457, were applied for 2 h at 201C. Appropriate FITC-conjugated secondary antibodies were incubated for 50 min and slides were mounted with medium containing DAPI.
Preparation of colonic cells and staining with Annexin V Primary cells were isolated from flushed colons with an enzyme mix of dispase I and collagenase I (Roche). Tissue pieces of 2 mm 2 were kept in enzyme mix suspension for 1 h at 371C. Tissue slurry was then centrifuged, and single cell supernatant was passed through 70 mm cell strainer. Cells were prepared for Annexin V labeling according to manufacturer's specifications (BD Biosciences, Mississauga, ON). Cells were analysed by FACScan (BD Biosciences).
In vivo BrdU-labeled proliferation assays Analyses of in vivo colonic cell proliferation was performed by intraperitoneal injection of a solution of 120 mg/kg of 5 0 -bromo-2 0 -deoxyuridine (BrdU, Sigma, St Louis, MO, USA) dissolved in normal saline (Velcich et al., 2002) into six sibling pairs of 6-month-old Ceacam1À/À and þ / þ mice. Mice were killed 2-24 h post-BrdU injections, colons were retrieved and paraformaldehyde-fixed sections were prepared for immunohistochemistry.
Carcinogen treatment and colon tumor preparations Twelve-week old age-matched or sibling Ceacam1À/À and þ / þ mice were injected intraperitoneally with azoxymethane (AOM, Sigma, St Louis, MO, USA) dissolved in saline at a dose of 10 mg/kg of body weight, once per week, for 8 weeks. The animals were systematically examined twice per week for appearance of clinical symptoms. Animals displaying discomfort were immediately killed. End points were defined as 19-20 weeks after the first injection. At least 10 mice of each genotype were tested per experiment and experiments were repeated three times. After killing the mice, the entire colon was removed, flushed with cold PBS, opened longitudinally and fixed flat on strips of 4% paraformaldehyde-soaked Whatman filter paper. Lesions of different sizes were identified under a dissection microscope and categorized by area as either >5, 2-5 or o2 mm 2 using a millimeter grid. After measurements were taken on the whole tissue, lesioned areas were embedded in paraffin for histological examination.
Quantification and statistical analysis Exposed films of Western blots were scanned, and images were analysed using ImageJ (Rasband, WS, ImageJ, US National Institutes of Health, Bethesda, Maryland, USA, http:// rsb.info.nih.gov/ij /, 1997-2005) . p21 and p27 immunoblots were normalized using actin as loading control. The ImageJ program was also used to calculate vascular density by establishing the amount of positive fluorescein signal on six microscope fields per tumor section using image thresholds and analysis of particles larger than 20 pixels. Positive signals were expressed as the square pixel area. Data was analysed using the Student's t-test for statistical significance. P-values were considered significant if o0.05. S.e. was calculated and represented in the bar graphs.
